Inovio To Streamline COVID-19 Vaccine Program Under New CEO
The company will shift development of INO-4800 to a booster strategy. It also announced it must conduct additional studies of the cervical dysplasia drug VGX-3100 after an FDA meeting.
You may also be interested in...
The US FDA appears to have concerns about the device used to administer the vaccine.
Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from CEPI and Bill Gates, it has a chance to prove the doubters wrong.
The company announced positive topline results for the drug in night vision disturbance and may conduct another pivotal trial as it focuses on myadriasis and presbyopia.